Insight Molecular Diagnostics
IMDX
56 hedge funds and large institutions have $67.8M invested in Insight Molecular Diagnostics in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 7 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
16% more capital invested
Capital invested by funds: $58.2M → $67.8M (+$9.56M)
0% more funds holding
Funds holding: 56 → 56 (0)
0.05% less ownership
Funds ownership: 2.27% → 2.22% (-0.05%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$3.41M |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$647K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$296K |
| 4 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$245K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$290K |
| 2 |
MFIM
Mesirow Financial Investment Management
Chicago,
Illinois
|
-$153K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$87.2K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$77K |
| 5 |
Morgan Stanley
New York
|
-$71.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RAM
51
Riggs Asset Management
Dallas,
Pennsylvania
| $2K | – | – | – |
|
52
Nisa Investment Advisors
St. Louis,
Missouri
| $2K | +$2.25K | +46 | New |
|
|
53
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | -$87.2K | -1,778 | -99% |
|
54
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $1K | – | – | – |
|
55
Osaic Holdings
Scottsdale,
Arizona
| $1K | +$686 | +14 | New |
|
|
56
AQR Capital Management
Greenwich,
Connecticut
| – | -$77K | -1,707 | Closed |
|
|
OAM
57
Oxford Asset Management
Oxford,
United Kingdom
| – | -$64K | -1,413 | Closed |
|
58
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$6K | -137 | Closed |
|
59
Group One Trading
Chicago,
Illinois
| – | -$2K | -55 | Closed |
|
IMDX Hedge Fund Activity: Q1 2020 in Review
56 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2020, worth a combined $67.8M — up 16% from $58.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new IMDX positions and 7 closed out — a net gain of 3 holders — while 20 added to existing stakes and 14 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $3.41M. The largest seller was Pura Vida Investments, cutting an estimated $290K.
- 56 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $67.8M of Insight Molecular Diagnostics stock for Q1 2020, up 16% quarter-over-quarter.
- 10 funds opened new Insight Molecular Diagnostics positions in Q1 2020 and 7 closed out, a net change of +3 holders.
- The largest Insight Molecular Diagnostics buyer in Q1 2020 was Broadwood Capital, an estimated $3.41M added.
- The largest Insight Molecular Diagnostics seller in Q1 2020 was Pura Vida Investments, an estimated $290K sold.
Based on aggregated 13F filings for Q1 2020.